Videos

Neurology experts discuss excessive daytime sleepiness (EDS) and narcolepsy treatment options.

The senior vice president of research at Vaxxinity talked about research for a potential vaccine for migraine prevention presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Karl Doghramji, MD, FAASM, DFAPA, provides an overview of the pharmacological treatment options for narcolepsy.

The associate professor of neurology at Mayo Clinic Rochester discussed specific findings from a simultaneous comparison of migraine medications in which certain treatments and classes were more effective. [WATCH TIME: 3 minutes]

The expert panel reviews unmet needs in treatment and management of dyskinesia and shares advice for physicians treating patients with Parkinson disease.

Drs Fernando Pagan, Robert A. Hauser, and Daniel Kremens highlight existing and emerging surgical and pharmacological options for treatment of dyskinesia in Parkinson disease.

The assistant professor in the department of neurology at the Albert Einstein College of Medicine and Montefiore Medical Center talked about predictive models in Alzheimer disease for clinical trials. [WATCH TIME: 5 minutes]

Stuart H. Isaacson, MD, FAAN, offers insight into the challenges faced when attempting to achieve long-term symptom control for patients with Parkinson disease.

The director and chief research scientist at Tisch MS Research Center of New York talked about a phase 2 data study on stem cell treatment for multiple sclerosis that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]

The panel discusses access challenges faced by patients with multiple sclerosis.

The panel discusses the role of shared decision-making to improve treatment outcomes for patients living with multiple sclerosis.

The director of the Mellen Center for MS at Cleveland Clinic talked about the ENSEMBLE study results that were presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

The assistant professor of neurology at Mayo Clinic spoke about understanding the phenotypes and epidemiology of autoimmune encephalitis at the 2023 AAN Annual Meeting. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending May 6, 2023. [WATCH TIME: 4 minutes]

The associate chief science officer at Kennedy Krieger Institute shared thoughts on the state of pediatric neurology and the significance of being named winner of the Sydney Carter Award. [WATCH TIME: 3 minutes]

The neurologist at Mayo Clinic in Jacksonville Florida provided perspective on his talk given at the 2023 AAN annual meeting on rapidly progressive dementia. [WATCH TIME: 6 minutes]

The associate professor of neurology at Mayo Clinic Rochester provided perspective on a new study presented at the 2023 AAN Annual Meeting assessing the treatment effectiveness of real-world patients with migraine. [WATCH TIME: 4 minutes]

The associate professor of neurology at Harvard Medical School talked about the subgroup analysis on ravulizumab in NMOSD that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, talked about a few of the studies on cenobamate for epilepsy presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Gabriel Pardo, MD, FAAN, describes the process that generic RRMS medications have to go through to be approved by the FDA, highlighting the abbreviated new drug application [ANDA] process.

Expert neurologists review availability of generic disease-modifying therapies [DMTs] and the effectiveness of reduced cost to the patient with RRMS

Neurology experts describe the goals of therapy for narcolepsy treatment.

Debra Stultz, MD, provides an overview of the available resources that are available for narcolepsy treatment.

The neurologist at Montefiore Medical Center, Albert Einstein College of Medicine, discussed his experience in establishing a neurology department committee on diversity, equity, and inclusion. [WATCH TIME: 5 minutes]

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided perspective on the in-depth testing neurologically healthy patients in the Brain Study will undergo. [WATCH TIME: 3 minutes]

The expert neurology panel shares their clinical experience with different formulations of amantadine in management of dyskinesia in patients with Parkinson disease.

The expert panel reviews the safety profile of amantadine DR/ER and who may be an ideal patient for its use in patients with Parkinson disease experiencing dyskinesia.

The manager of Clinical Development-Research at Linus Health discussed potential avenues of research for the DCTclock and expanding its capabilities as a potential detector of cognitive decline. [WATCH TIME: 3 minutes]

An expert in the management of Parkinson disease discusses the key role that shared decision-making plays in the modern treatment paradigm.

The neurology resident from the University of Pennslyvania talked about stroke prevalence in the United States between 1999 and 2018 as part of a presentation at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]